Canada· CA-DIN-02518627
MINJUVI
A tafasitamab product containing tafasitamab, registered in Canada by INCYTE CORPORATION. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Tafasitamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX12 (tafasitamab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Tafasitamab · ATC L01FX12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tafasitamab costs, country by country.
Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tafasitamab · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$272.81
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- TAFASITAMAB
- Manufacturer
- INCYTE CORPORATION
- Country
- Canada (CA)
- ATC code
- L01FX12
- ATC class
- Tafasitamab
- Defined daily dose
- 60 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for tafasitamab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tafasitamab · interactions on record
58 records
- 28 severe
- 30 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tafasitamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandMINJUVIOrifarm Oy
- United StatesMONJUVIIncyte Corporation
- CzechiaMINJUVIIncyte Biosciences Distribution B.V., Amsterdam
- SpainMINJUVI 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- FranceMINJUVI 200 mg, poudre pour solution à diluer pour perfusionINCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- United KingdomMinjuvi 200mg powder for concentrate for solution for infusion vialsIncyte Biosciences UK Ltd
- BelgiumMinjuvi 200 mgIncyte Biosciences Distribution
- IcelandMinjuviIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Minjuvi
- Liechtenstein · Minjuvi
- Norway · Minjuvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/12f1e358-9552-405e-8a70-a466b19e22dc GET /v1/drugs/12f1e358-9552-405e-8a70-a466b19e22dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02518627",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01FX12",
"schedule": [
"Prescription",
"Schedule D"
],
"drug_code": "100793",
"strengths": [
"200 MG"
],
"ahfs_class": null,
"substances": [
"TAFASITAMAB"
],
"product_categorization": null
}See everything about tafasitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.